Abstract
Natalizumab Reduces Serum Concentrations of Neurofilament Light Chain in Secondary Progressive Multiple Sclerosis Patients From the Phase 3 ASCEND Study (S12.008)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have